HAMBURG, Germany and OXFORD, England, August 28 Evotec AG (Frankfurt Stock Exchange: EVT) is pleased to invite you to awebcast presentation and conference call on detailed Phase II data for itslead compound EVT 201 in the treatment of insomnia on 5 September 2007 at11.00 am CET / 10.00 am GMT / 5.00 am EST / 7.00 pm AEST
The Evotec speakers at the worldsleep07 congress and in the webcast andconference call will be:
- Dr John Kemp, Chief Research and Development Officer
- Dr Tim Tasker, Executive Vice President Clinical Development
Evotec will host a poster presentation on the study results at theworldsleep07 congress from 4.00 to 6.00 pm AEST time at the Sofitel ReefHotel, 35-41 Wharf Street, Cairns, Australia (poster No PO649). Following theconference presentation, Evotec will hold the webcast and conference call todiscuss the results. Positive headline results of this first Phase II studyin 67 patients were released on 4 June 2007.
To attend the webcast and conference call, please dial in using thefollowing phone numbers:
Please dial in 10 minutes before the beginning of the conference.
The presentation will be available at the Evotec homepagehttp://www.evotec.com.
Evotec expects the results from a second Phase II study in 135 elderlyinsomniacs to be available in October 2007.
Although certain aspects of insomnia are addressed by current treatments,there is no drug yet available which meets all the needs of insomnia patients.
About EVT 201
EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAAreceptor complex. Acting on GABAA receptors it addresses the gold standardmechanism for insomnia with more than 90% of current insomnia drugs usingthis mechanism. Importantly, however, its close to ideal half life of 3 to 4hours and its partial agonist activity gives EVT 201 a differentiatedpreclinical profile and mechanism of action.
The headline results of the first Phase II study with EVT 201 were verypositive in terms of all aspects of the problems faced by insomniacs, i.e.sleep onset and sleep maintenance and yet the patients didn't feel any drughang-over effects after waking in the morning. Furthermore, in two previousPhase I/II proof-of-principle studies in subjects with induced insomnia, EVT201 significantly reduced Wake After Sleep Onset (WASO) while significantlyincreasing the Total Sleep Time (TST) and quality of sleep with no subjectiveresidual effects. The studies were conducted in a sleep laboratory settingusing the traffic noise model of insomnia in healthy male volunteers. In thissetting an average of 52 decibels of recorded traffic noise is playedthroughout the night thereby provoking insomnia. This model has been used toevaluate several insomnia treatments currently in development and on themarket. EVT 201 showed no tolerance/dependence liabilities in pre-clinicalstudies and no interaction with alcohol.Australia +61-(2)-8223-9234 Germany +49-(69)-9897-2631 Switzerland +41-(44)-800-9659 UK +44-(20)-7138-0814 USA +1-(718)-354-1157 PIN code: 5301349
SOURCE Evotec AG